Press Release
For More Information

Sharon Granskog
Phone: 847-285-6619
Cell: 847-280-1273

FOR IMMEDIATE RELEASE:

  3/14/2018

 AVMA president testifies at congressional hearing on animal drug user fees

​American Veterinary Medical Association (AVMA) President Dr. Michael Topper testified today in front of the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health in favor of proposed reauthorization of the Animal Drug and Animal Generic Drug User Fee Amendments. Timely passage of this legislation is needed to continue programs that help increase the availability of pharmaceutical resources in the treatment of animal diseases.

“By providing new animal drugs with a predictable pathway to market, these fees help provide veterinarians with access to new and additional tools that can potentially improve treatment outcomes, provide alternatives to existing therapies, fill unmet medical needs in veterinary medicine, and ultimately improve patient care, which is the center of veterinary practice,” Dr. Topper told members of the committee.

Passage of these amendments would reauthorize the U.S. Food and Drug Administration’s (FDA) Center for Veterinary Medicine’s collection of animal drug and animal generic drug user fees from the drugs’ sponsors, which go toward expediting the review of these new therapies. These efforts are crucial because currently, there simply aren’t enough FDA-approved animal drugs to address the diversity of species and conditions that veterinarians treat.

“Comparisons show there are 23 times as many approved labeled indications for human use than there are for animal use,” said Dr. Topper. “With seven major species and innumerable minor species, all of which have many varied diseases and conditions to treat, veterinary access to FDA-approved medications for use in numerous diverse species is critical.”

# # #